The Importance of Inflammatory and Angiogenic Markers in the Evaluation of Early Cardiovascular Disease Risk in Women with Hypertensive Disorders of Pregnancy

The Importance of Inflammatory and Angiogenic Markers in the Evaluation of Early Cardiovascular Disease Risk in Women with Hypertensive Disorders of Pregnancy

Background: Women with hypertensive disorders of pregnancy (HDP) have a significantly higher risk of developing cardiovascular diseases later in life. The stratification of this risk using biomarkers during pregnancy can help to identify these women and apply early prevention. Objective: We aimed to...

Full description

Bibliographic Details
Main Authors:	Tatjana Maselienė, Emilija Struckutė, Rūta Breivienė, Diana Ramašauskaitė, Vilma Dženkevičiūtė
Format:	Article
Language:	English
Published:	MDPI AG 2023-09-01
Series:	Journal of Cardiovascular Development and Disease
Subjects:	hypertensive disorders of pregnancy preeclampsia angiogenic factors placental growth factor soluble fms-like tyrosine kinase-1 interleukin-6
Online Access:	https://www.mdpi.com/2308-3425/10/10/407

Similar Items

Performance of sFlt-1/PIGF Ratio for the Prediction of Perinatal Outcome in Obese Pre-Eclamptic Women
by: Anne Karge, et al.
Published: (2022-05-01)

No association between early antiretroviral therapy during pregnancy and plasma levels of angiogenic factors: a cohort study
by: Ameyo Djeha, et al.
Published: (2019-12-01)

Placental growth fActor Repeat sampling for Reduction of adverse perinatal Outcomes in women with suspecTed pre-eclampsia: study protocol for a randomised controlled trial (PARROT-2)
by: Alice Hurrell, et al.
Published: (2022-09-01)

Nephrotic syndrome due to preeclampsia before 20 weeks of gestation: a case report
by: Tomo Suzuki, et al.
Published: (2020-06-01)

The Impact of Coexisting Gestational Diabetes Mellitus on the Course of Preeclampsia
by: Katarzyna Pankiewicz, et al.
Published: (2022-10-01)

Soluble fms-like tyrosine kinase 1 and placental growth factor ratio for predicting preeclampsia in elderly gravida
by: Vorapong Phupong, et al.
Published: (2020-04-01)

Predictive value of the sFlt-1/PlGF ratio for preeclampsia in twin pregnancies: a retrospective study
by: Satoshi Shinohara, et al.
Published: (2021-10-01)

Therapeutic Plasma Exchange in Early-Onset Preeclampsia: A 7-Year Monocentric Experience
by: Antonella Iannaccone, et al.
Published: (2023-06-01)

Circulating angiogenic factors and HIV among pregnant women in Zambia: a nested case–control study
by: Megan E. Smithmyer, et al.
Published: (2021-07-01)

Correlation of sFlt/PlGF ratio with severity of preeclampsia in an Indian populationAJOG Global Reports at a Glance
by: Namrata Kumar, MD, MRCOG, EFOG, FACOG, et al.
Published: (2023-05-01)

MIF Increases sFLT1 Expression in Early Uncomplicated Pregnancy and Preeclampsia
by: Qing Yong, et al.
Published: (2023-06-01)

Serum Angiogenic and Anti-angiogenic Markers in Pregnant Women with Placenta Percreta
by: Adnan İncebıyık, et al.
Published: (2018-02-01)

sFlt-1 Is an Independent Predictor of Adverse Maternal Outcomes in Women With SARS-CoV-2 Infection and Hypertensive Disorders of Pregnancy
by: Jose Antonio Hernandez-Pacheco, et al.
Published: (2022-05-01)

A cross sectional study to assess the sFlt-1:PlGF ratio in pregnant women with and without preeclampsia
by: Vivek Pant, et al.
Published: (2019-07-01)

Association between the high soluble fms-like tyrosine kinase-1 to placental growth factor ratio and adverse outcomes in asymptomatic women with early-onset fetal growth restriction
by: Satoshi Shinohara, et al.
Published: (2017-07-01)

Use of serum and urinary soluble sFlt-1 and PLGF in the diagnosis of preeclampsia
by: Ping Tang, et al.
Published: (2017-01-01)

THE ROLE OF THE PIGF/SFLT-1 RELATIONSHIP IN PREDICTING PREECLAMPSIA (LITERATURE REVIEW)
by: Irina Venzkovskaya, et al.
Published: (2019-04-01)

Angiogenic Biomarker Placental Growth Factor (PLGF) in the Prediction and Diagnosis of Placental Dysfunction in Pre-eclampsia: A Cohort Study
by: Mandeep Kaur, et al.
Published: (2023-06-01)

Serum placental growth factor and soluble fms-like tyrosine kinase-1 in preeclamptic women at their third trimester of pregnancy
by: Nesreen Nasser, et al.
Published: (2020-12-01)

Similar Pro- and Antiangiogenic Profiles Close to Delivery in Different Clinical Presentations of Two Pregnancy Syndromes: Preeclampsia and Fetal Growth Restriction
by: Weronika Dymara-Konopka, et al.
Published: (2023-01-01)

Correlation between N‐terminal pro‐atrial natriuretic peptide, corin, and target organ damage in hypertensive disorders of pregnancy
by: Wei Zhang, et al.
Published: (2022-05-01)

The Role of Soluble fms-Like Tyrosine Kinase-1 Markers and Vascular Endothelial Growth Factor in Comparison with Color Doppler Sonography for Detecting Plasenta Accreta
by: Elhan Naghshineh, et al.
Published: (2019-05-01)

Impact of Angiogenic and Cardiovascular Biomarkers for Prediction of Placental Dysfunction in the First Trimester of Pregnancy
by: Madalina Nicoleta Nan, et al.
Published: (2023-04-01)

Maternal Serum Angiogenic Profile and Its Correlations with Ultrasound Parameters and Perinatal Results in Normotensive and Preeclamptic Pregnancies Complicated by Fetal Growth Restriction
by: Weronika Dymara-Konopka, et al.
Published: (2023-06-01)

Increased placental sFlt-1 but unchanged PlGF expression in late-onset preeclampsia
by: Laura Ehrlich, et al.
Published: (2017-04-01)

An Examination of the Effect of Aspirin and Salicylic Acid on Soluble Fms-like Tyrosine Kinase-1 Release from Human Placental Trophoblasts
by: Jiawu Zhao, et al.
Published: (2024-01-01)

Analysis of Methyldopa Therapy on sFlt-1 Antiangiogenic Levels in Patients with Severe Preeclampsia
by: Teri Wina Herwati, et al.
Published: (2018-04-01)

Soluble fms-like tyrosine kinase-1 and vascular endothelial growth factor: Novel markers for unexplained early recurrent pregnancy loss
by: Mahmoud Fathy Hassan
Published: (2014-03-01)

Enhanced Serum Levels of sFlt1: Impact on Materno–Fetal CMV Transmission
by: Lukas Penka, et al.
Published: (2020-04-01)

Predicting Time to Delivery in Hypertensive Disorders: Assessing PlGF and sFlt-1 with the Novel Parameter ‘Mtp-Multiples of a Normal Term Placenta’
by: Valentina Giardini, et al.
Published: (2024-03-01)

Altered expression of vascular endothelial growth factor, vascular endothelial growth factor receptor-1, vascular endothelial growth factor receptor-2, and Soluble Fms-like Tyrosine Kinase-1 in peripheral blood mononuclear cells from normal and preeclamptic pregnancies
by: Zaima Ali, et al.
Published: (2019-01-01)

Reference ranges of anti‐Müllerian hormone and interaction with placental biomarkers in early pregnancy: the Generation R Study, a population-based prospective cohort study
by: R H M Dykgraaf, et al.
Published: (2023-02-01)

The Role of the Aryl Hydrocarbon Receptor in Vascular Factors Related to Preeclampsia in a Smoking Mouse Model
by: Ho-Yeon Kim, et al.
Published: (2024-01-01)

Prognostic value of serum soluble FMS-like tyrosine kinase (sFlt-1) levels in pre-eclampsia and eclampsia; a prospective cohort study
by: Ahmed M. Abbas, et al.
Published: (2018-07-01)

Added value of mean blood pressure and placental growth factor in the early detection of pre-eclampsia among gabonese women
by: Elisabeth Lendoye, et al.
Published: (2024-01-01)

Maternal serum soluble fms-like tyrosine kinase-1–to–placental growth factor ratio distinguishes growth-restricted from non–growth-restricted small-for-gestational-age fetusesAJOG Global Reports at a Glance
by: Prithi Rajiv, MD, et al.
Published: (2024-02-01)

Human umbilical cord mesenchymal stem cell derived exosomes (HUCMSC-exos) recovery soluble fms-like tyrosine kinase-1 (sFlt-1)-induced endothelial dysfunction in preeclampsia
by: Xinwen Chang, et al.
Published: (2023-08-01)

Placenta crucially affects formation of fetal congenital heart disease
by: V. I. Tsibizova, et al.
Published: (2022-03-01)

A Maternally Sequestered, Biopolymer‐Stabilized Vascular Endothelial Growth Factor (VEGF) Chimera for Treatment of Preeclampsia
by: Omar C. Logue, et al.
Published: (2017-12-01)

The PLANES study: a protocol for a randomised controlled feasibility study of the placental growth factor (PlGF) blood test-informed care versus standard care alone for women with a small for gestational age fetus at or after 32 + 0 weeks’ gestation
by: Joanna Gent, et al.
Published: (2020-11-01)